Provided by Tiger Trade Technology Pte. Ltd.

Connect Biopharma Holdings Ltd.

0.9447
+0.03934.34%
Post-market: 0.9333-0.0114-1.21%19:56 EDT
Volume:1.22M
Turnover:1.15M
Market Cap:59.48M
PE:-0.79
High:0.9689
Open:0.9000
Low:0.8900
Close:0.9054
52wk High:3.82
52wk Low:0.8501
Shares:62.96M
Float Shares:21.58M
Volume Ratio:0.03
T/O Rate:5.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1933
EPS(LYR):-1.0000
ROE:-140.51%
ROA:-69.75%
PB:2.21
PE(LYR):-0.94

Loading ...

Connect Biopharma Price Target Maintained with a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 02

3 Penny Stocks on Investors’ Radar, October 1

TIPRANKS
·
Oct 01

US Research Roundup-Amrize, Dexcom, Lennar

Reuters
·
Oct 01

Connect Biopharma Holdings Ltd : Btig Cuts Target Price to $5 from $10

THOMSON REUTERS
·
Oct 01

NASD Most Active Issues

Dow Jones
·
Oct 01

Top Midday Gainers

MT Newswires Live
·
Oct 01

Lake Street Sticks to Its Buy Rating for Connect Biopharma Holdings (CNTB)

TIPRANKS
·
Sep 30

Why Is Penny Stock Connect Biopharma (CNTB) Up 98% Today?

TIPRANKS
·
Sep 30

Connect Biopharma reports positive Phase 2 COPD results

TIPRANKS
·
Sep 30

Connect Biopharma announces results from global Phase 2 study of rademikibart

TIPRANKS
·
Sep 30

Connect Biopharma Says Phase 2 Trial Shows Rademikibart Cuts COPD Treatment Failure Rate 81% Through Week 4

Reuters
·
Sep 30

Connect Biopharma - Rademikibart Reduced Treatment Failure Rate by 81% Through One Month in Phase 2 Study

THOMSON REUTERS
·
Sep 30

Connect Biopharma - to Engage FDA for Phase 3 Program for Rademikibart in Copd

THOMSON REUTERS
·
Sep 30

Connect Biopharma Announces Positive Preliminary Topline Data from Its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with Copd and Type 2 Inflammation

THOMSON REUTERS
·
Sep 30

Connect Biopharma - Rademikibart Reduced Hospitalizations or Ed Visits for Acute Copd Exacerbations by 100%

THOMSON REUTERS
·
Sep 30

Connect Biopharma - Rademikibart Well Tolerated with Lower Incidence of Adverse Events than Placebo

THOMSON REUTERS
·
Sep 30

Connect Biopharma price target lowered to $5 from $8 at Oppenheimer

TIPRANKS
·
Sep 22

US Research Roundup-Boeing, Twilio, WP Carey

Reuters
·
Sep 22

H.C. Wainwright Sticks to Its Buy Rating for Connect Biopharma Holdings (CNTB)

TIPRANKS
·
Sep 22

Connect Biopharma Price Target Maintained with a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 17